Pharmacological chaperones:: a new twist on receptor folding

被引:191
作者
Morello, JP
Petäjä-Repo, UE
Bichet, DG
Bouvier, M
机构
[1] Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada
[2] Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland
[3] Hop Sacre Coeur, Ctr Rech, Montreal, PQ H4J 1C5, Canada
[4] Hop Sacre Coeur, Serv Nephrol, Montreal, PQ H4J 1C5, Canada
关键词
D O I
10.1016/S0165-6147(00)01575-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protein misfolding is at the root of several genetic human diseases. These diseases do not stem from mutations within the active domain of the proteins, but from mutations that disrupt their three-dimensional conformation, which leads to their intracellular retention by the quality control apparatus of the cell. Facilitating the escape of the mutant proteins from the quality control system by lowering the temperature of the cells or by adding chemicals that assist folding (chemical chaperones) can result in proteins that are fully functional despite their mutation. The discovery that ligands with pharmacological selectivity (pharmacological chaperones) can rescue the proper targeting and function of misfolded proteins, including receptors, might help to develop new treatments for 'conformational diseases'.
引用
收藏
页码:466 / 469
页数:4
相关论文
共 27 条
  • [1] 5-fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985):: An orally active arginine vasopressin antagonist with selectivity for V2 receptors
    Albright, JD
    Reich, MF
    Delos Santos, EG
    Dusza, JP
    Sum, FW
    Venkatesan, AM
    Coupet, J
    Chan, PS
    Ru, X
    Mazandarani, H
    Bailey, T
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (14) : 2442 - 2444
  • [2] Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO
  • [3] 2
  • [4] Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z:: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency
    Burrows, JAJ
    Willis, LK
    Perlmutter, DH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) : 1796 - 1801
  • [5] Conformational disease
    Carrell, RW
    Lomas, DA
    [J]. LANCET, 1997, 350 (9071) : 134 - 138
  • [6] ALTERED CHLORIDE-ION CHANNEL KINETICS ASSOCIATED WITH THE DELTA-F508 CYSTIC-FIBROSIS MUTATION
    DALEMANS, W
    BARBRY, P
    CHAMPIGNY, G
    JALLAT, S
    DOTT, K
    DREYER, D
    CRYSTAL, RG
    PAVIRANI, A
    LECOCQ, JP
    LAZDUNSKI, M
    [J]. NATURE, 1991, 354 (6354) : 526 - 528
  • [7] PROCESSING OF MUTANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS TEMPERATURE-SENSITIVE
    DENNING, GM
    ANDERSON, MP
    AMARA, JF
    MARSHALL, J
    SMITH, AE
    WELSH, MJ
    [J]. NATURE, 1992, 358 (6389) : 761 - 764
  • [8] Desnick R.J., 1995, The Metabolic and Molecular Bases of Inherited Disease, P2741
  • [9] CHLORIDE CONDUCTANCE EXPRESSED BY DELTA-F508 AND OTHER MUTANT CFTRS IN XENOPUS OOCYTES
    DRUMM, ML
    WILKINSON, DJ
    SMIT, LS
    WORRELL, RT
    STRONG, TV
    FRIZZELL, RA
    DAWSON, DC
    COLLINS, FS
    [J]. SCIENCE, 1991, 254 (5039) : 1797 - 1799
  • [10] Setting the standards: Quality control in the secretory pathway
    Ellgaard, L
    Molinari, M
    Helenius, A
    [J]. SCIENCE, 1999, 286 (5446) : 1882 - 1888